Adult Brain Tumor Consortium (ABTC)

描述（由申请人提供）：本申请响应RFA-CA-08-504，旨在继续支持原发性中枢神经系统癌症成人的I期和II期治疗研究，并继续开展最初在RFA CA-04-001下资助的活动。这一单一的合并申请来自目前资助的两个独立的成人脑肿瘤联盟：脑肿瘤治疗新方法（NABTT）和北美脑肿瘤联盟（NABTC），旨在最大限度地提高临床试验效率并加强对转化研究的支持。成人脑肿瘤联盟（ABTC）将利用在以前的奖项期间培养的科学专业知识和经验，保留大多数NABTT和NABTC成员机构以及临床试验，药理学，生物统计学和神经病理学领导地位。ABTC的共同首席研究员（Stuart Grossman和Michael Prados）自1994年成立以来一直指导NABTT和NABTC的活动。ABTC将利用NABTT运营办公室（Stuart Grossman和Joy Fisher）、NABTC生物统计学家（Kathleen Lamborn）、来自NABTT和NABTC的药理学家（Jeff Supko和John Kuhn）、神经影像学（Greg Sorensen和Sarah纳尔逊）和神经病理学（Ken Aldape）专家的技能和经验。根据预先确定的标准，ABTC指导委员会将评估潜在的成员网站，解雇表现不佳的成员网站，并评估竞争性申请，并为药理学，成像和相关生物学研究提供资金。ABTC的委员会结构将侧重于与NIH，SPORE，合作团体，机构转化研究，制药公司和新的多学科方法的互动。一个经验丰富的国际外部咨询委员会将为ABTC提供宝贵的意见。这个新合并的联盟将致力于开发更有效的成人脑肿瘤治疗方法：1）通过开展1-2期临床试验，安全有效地将新型抗癌药物引入高级别原发性脑肿瘤的治疗，2）积极寻求与其他NCI资助的临床试验机制和致力于寻找有希望的成人脑肿瘤新治疗方法的研究人员的合作;和3）适当地将药代动力学和药效学终点（包括成像和转化实验室研究）纳入1-2期研究。

DESCRIPTION (provided by applicant): This application responds to RFA-CA-08-504 which is intended to continue support for Phase 1 and 2 treatment studies in adults with primary central nervous system cancers and to continue the activities that were funded initially under RFA CA-04-001. This single, consolidated application from the two currently funded separate adult brain tumor consortia: New Approaches to Brain Tumor Therapy (NABTT) and North American Brain Tumor Consortium (NABTC) is designed to maximize clinical trial efficiency and enhance support for translational research. The Adult Brain Tumor Consortium (ABTC) will capitalize on the scientific expertise and experience that has been nurtured during the previous award periods by retaining the majority of the NABTT and NABTC member institutions as well as clinical trial, pharmacology, biostatistics, and neuropathology leadership. The Co-Principal Investigators of the ABTC (Stuart Grossman and Michael Prados) have directed the activities of NABTT and NABTC since their inception in 1994. ABTC will utilize the skills and experience of The NABTT Operations Office (Stuart Grossman and Joy Fisher), the NABTC biostatistician (Kathleen Lamborn), pharmacologists from NABTT and NABTC (Jeff Supko and John Kuhn), and neuro-imaging (Greg Sorensen and Sarah Nelson) and neuropathology (Ken Aldape) experts. Based on predetermined criteria, the ABTC Steering Committee will evaluate potential member sites, dismiss underperforming member sites, and evaluate competitive applications and award funds for pharmacologic, imaging, and correlative biology research. ABTC's committee structure will focus on interactions with the NIH, SPOREs, cooperative groups, institutional translational research, pharmaceutical companies, and novel multidisciplinary approaches. An experienced and international External Advisory Board will provide valuable input to ABTC. This newly consolidated consortium will strive to develop more effective therapies for adult brain tumors by: 1) safely and efficiently introducing novel anticancer agents into the treatment of high grade primary brain tumors through the conduct of Phase 1-2 clinical trials, 2) Proactively seeking collaborations with other NCI-funded clinical trials mechanisms and researchers devoted to finding promising new treatment approaches for adult brain tumors; and 3) Incorporating pharmacokinetic and pharmacodynamic endpoints (including imaging and translational laboratory studies) as appropriate into Phase 1-2 studies.